Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates.

Although this difference did not reach statistical significance when each time point was analyzed separately, we hypothesized that sGP-specific levels of antibodies may be a correlate of protection, regardless of post-vaccination challenge time point, supported by our finding that macaques that were protected at 1 year diverged in their immune response from unprotected macaques shortly after vaccination.

also in 111,027 other papers

Survivors showed a trend toward higher antibody responses than non-survivors, but the kinetics and durability of vaccine-specific antibody titers were not statistically different across survivors and non-survivors ( Figure 1C ).

also in 53,322 other papers